Skip to main content

Advertisement

Table 4 Prevalence and incidence of gametocytes during the study (ITT population)

From: Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India

  DP n/N (%) A + M n/N (%)
Gametocyte prevalence 1
Day 7 7/98 (7.1) 0/46 (0.0)
Day 14 5/94 (5.3) 0/44 (0.0)
Day 28 0/89 (0.0) 0/42 (0.0)
Day 42 0/85 (0.0) 0/41 (0.0)
Day 63 0/81 (0.0) 0/41 (0.0)
Overall (day 7 - day 63) 9/98 (9.2) 0/46 (0.0)
Gametocyte incidence 2
Day 7 7/98 (7.14) 0/46 (0.0)
Day 14 2/94 (2.13) 0/44 (0.0)
Day 28 0/89 (0.0) 0/42 (0.0)
Day 42 0/85 (0.0) 0/41 (0.0)
Day 63 0/81 (0.0) 0/41 (0.0)
Person-gametocyte-weeks 3 18/814 (22.1) 0/391 (0.0)
  1. DP = dihydroartemisinin-piperaquine; A + M = artesunate-mefloquine.
  2. 1Calculated, at a given time, as number of patients with gametocytes at that time divided by the number of patients having reached that time;
  3. 2Calculated, at a given time interval, as number of new patients with gametocytes in that interval divided by the number of patients having reached the end of that interval;
  4. 3Calculated as number of weeks in which blood slides were positive for gametocytes during the whole study (up to a maximum duration of 70 days) divided by the number of all follow-up weeks and expressed per 1,000 person-weeks.